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AbstTact Somatostatin a d its anologue SMS 201-995 inhibit high voltage-activated (HVA) Ca 2÷ currents in the rat insulinoma cell line RINm5F 
which stably express cloned human somatostatin receptor subtype 2 (hSSTR2). In contrast, neither somatostatin nor SMS 201-995 suppresses the 
HVA Ca 2÷ currents in RINm5F which stably express cloned hSSTRI. These results uggest hat somatostatin-induced inhibition of HVA Ca 2+ 
currents is mediated by a specific receptor subtype and that inhibition of calcium influx through HVA Ca 2+ channels i one of the mechanisms of
SMS 201-995 action on inhibitory processes of hormone secretion and cell proliferation. 
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1. Introduction 
Somatostatin, a tetradecapeptide originally discovered as a 
hypothalamic nhibitor of growth hormone secretion [ 1], exerts 
diverse biological actions in many other tissues, including inhi- 
bition of secretory and proliferative processes [2, 3]. The biolog- 
ical functions of somatostatin are mediated by its specific recep- 
tors which are coupled to GTP-binding (G) proteins [4]. 
Various somatostatin analogues have been developed for clini- 
cal applications to inhibit hormone secretion and cell prolifera- 
tion [5]. One of the somatostatin analogues, SMS 201-995, has 
been approved for the treatment of endocrine tumors [6]. How- 
ever, the mechanism of its action is still unknown. Intracellular 
calcium ([Ca2÷]i) is the principal signal for many cellular func- 
tions, including hormone secretion and cell proliferation [7,8], 
Although somatostatin has been shown to inhibit calcium in- 
flux through voltage-dependent calcium channels (VDCC) 
[9-12], the effect of SMS 201-995 on VDCC is not yet evaluated, 
Recently, we have identified five subtypes of human somato- 
statin receptor (hSSTR1-5), the mRNAs of which are ex- 
pressed in a tissue-specific manner [13-15]. Of these, hSSTR2 
has been shown to have the highest binding affinity for SMS 
201-995 [16]. In addition, we have found that the efficacy of 
SMS 201-995 in the treatment of endocrine tumors may de- 
pend, at least in part, on the expression of hSSTR2 in the 
tumors [16]. In this report, we show that both somatostatin and 
SMS 201-995 inhibit high-voltage-activated (HVA) Ca 2÷ cur- 
rents in insulin-secreting R INm5F cells stably expressing 
hSSTR2, while somatostatin does not inhibit HVA Ca 2÷ cur- 
rents in R INm5F cells expressing hSSTR 1, suggesting that inhi- 
bition of calcium influx through VDCC, which is mediated by 
the specific receptor subtype hSSTR2, could contribute in part 
*Corresponding author. Fax: (81) (43) 221 7803. 
to the suppressive effects of SMS 201-995 on hormone secretion 
and cell proliferation in the treatment of endocrine tumors. 
2. Materials and methods 
2.1. Cell culture 
RINm5F cells were grown in monolayers in Dulbecco's modified 
Eagle medium (DMEM) containing 10% fetal bovine serum (Gibco/ 
BRL) in an atmosphere of 5% CO2 and 95% air at 37°C. 
2.2. Establishment of RINm5F cells stably expressing human 
somatostatin receptors 
A PstlIXmnI fragment of the hSSTR1 gene [13], and a BamHIIXbaI 
fragment of the hSSTR2 gene [13] were inserted into mammalian ex- 
pression vector, pCMV6b. RINm5F cells stably expressing hSSTR1 or 
hSSTR2 were established as previously described [13]. Briefly, the ex- 
pression plasmids were cotransfected with pSV2neo into RINm5F ceils 
using Lipofectin reagent (Gibco/BRL). Stable transformants were se- 
lected in the culture medium containing G418 at 400 gg/ml. For control 
cells, RINm5F cells transfected with plasmid vector alone were used. 
2.3. RNA blot analysis 
Total cellular RNA was isolated from transfected and untransfected 
RINm5F cells by guanidinium isothiocyanate/CsCl procedure. For 
RNA transfer blots, 20 gg of total cellular RNA were denatured with 
formaldehyde, lectrophoresed on 1% agarose gel, and transferred to 
a nylon membrane. Membranes were hybridized with a 32P-labeled 
PstlIXmnI (nucleotide -98 ~ + 1400, relative to the translation start site) 
hSSTR1 or BamHIIXbaI (nucleotide -81 ~ +1215) hSSTR2 gene probe 
using high-stringency conditions (42°C; 50% formamide, 0.75 M NaC1/ 
75 mM sodium citrate, 2 x Denhardt's olution (Denhardt's olu- 
tion = 0.02% bovine serum albumird0.02% Ficoll/0.02% polyviny- 
lpyrrolidone), 20 mM sodium phosphate buffer (pH 6.5), 0.1% Na- 
DodSO 4, 100 gg of sonicated, enatured salmon testis DNA per ml, 
10% dextran sulfate, and 3~4 x 106 clam of probe per ml) [13]. 
2.4. Binding experiments 
The incubation medium used for the binding experiments was a 
mixture of l mg/ml bacitracin, 0.1 mM p-amidinophenyl methanesul- 
fonyl fluoride hydrochloride, 20 pM [125I-Tyrll]somatostatin-14 in 
the absence or presence of somatostatin a d SMS 201-995 at various 
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concentrations as indicated in Fig. lB. After incubation for I h at 20°C, 
the cells were washed twice with the ice-cold phosphate-buffered saline 
and solubilized in 1 ml of 1 N NaOH, and the radioactivity was meas- 
ured in a y-counter. 
2.5. Electrophysiological recordings 
The whole-cell voltage clamp technique was carried out to record 
VDCC currents in RINm5F cells [17]. Ba 2÷ was used as a charge carrier 
for measurement of VDCC currents. The extracellular recording solu- 
tion was a mixture of 20 mM Ba(OH)2, 110 mM N-methyl-D-glucamine, 
10 mM tetraethylammonium chloride, 140 mM methanesulfonate, 
20 mM 4-aminopyridine, and 10 mM MOPS (pH 7.4). The pipette 
solution was a mixture of 140 mM cesium aspartate, 10 mM EGTA, 
5 mM Mg-ATP, and 10 mM MOPS (pH 7.2). GTPTS was added to the 
pipette solution at a final concentration of 200 pM. Pertussis toxin 
(PTX) was added to the culture medium at a final concentration f200 
ng/ml for 12 h before recordings. After achieving the whole-cell config- 
uration of the patch-clamp recording, the cells were maintained at a 
holding potential of -80 mV. VDCC currents were recorded by depo- 
larizing the membrane to test pulse potentials from -40 mV to +80 mV 
in +10 mV steps at every 10 s. The effects of somatostatin and SMS 
201-995 on peak VDCC currents were evaluated at a test potential of 
+20 mV. Test agents were dissolved in the extracellular solution and 
applied to a recording chamber (0.3 ml in volume) at a flow rate of 
6 ml/min. The recordings were performed at room temperature (20- 
22°C). Values are expressed as mean _+ S.E.M. Statistical nalyses were 
conducted using Student's t-test. 
2.6. cAMP measurement 
The transfected RINm5F cells were split into 24-well plates and 
grown to confluency in the culture medium described above. The cells 
were washed with DMEM containing 1mg/ml bovine serum albumin 
and incubated for 45 min at 37°C in 2 ml of the same buffer or the same 
buffer containing 1-methyl-3-isobutylxanthine (0.2 mM) with forskolin 
(1 mM) or a combination of forskolin and somatostatin (100 nM). 
cAMP levels were quantified by enzyme immunoassay s stem (Amer- 
sham) as described [18]. 
3. Results 
3.1. Establishment of RINm5F cells stably expressing hSSTR1 
and hSSTR2 
RINm5F subclonal cells which most abundantly express the 
hSSTR1 (designated R1-7) or hSSTR2 (designated R2-14) 
were selected by RNA blot and binding analyses. As shown in 
Fig. 1A, RNA blot analysis revealed a 2.0 kb or a 1.8 kb 
transcript in R1-7 or R2-14 cells, respectively, whereas neither 
hSSTR1 nor hSSTR2 mRNA was detected in R INm5F cells 
transfected with plasmid vector alone. 
3.2. Competitive binding experiments 
To ascertain that hSSTR1 and hSSTR2 proteins are ex- 
pressed in these cells, we performed competitive binding exper- 
iments. While no specific binding was detected in R INm5F cells 
transfected with vector alone, both R1-7 and R2-14 cells 
showed specific binding of [125I-TyrH]somatostatin (see Fig. 1, 
legend). In competition binding experiments, omatostatin-14 
potently inhibited [~25I-Tyr~l]somatostatin binding in R 1-7 and 
R2-14 cells with a half-maximal inhibitory concentration (IC50) 
value of 1.0 nM in both cells. SMS 201-995 inhibited [125I- 
TyrH]somatostatin binding in R2-14 and R1-7 cells with an 
IC50 value of 13 nM and > 1/IM, respectively (Fig. 1B). 
3.3. Effects of  somatostatin and SMS 201-995 on VDCC 
currents in hSSTRl-expressing and hSSTR2-expressing 
RINm5F cells 
Since the VDCC currents detected in R INm5F cells used in 
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Fig. 1. (A) Northern blot analyses of hSSTR1 and 2 mRNAs in trans- 
fected RINm5F cells. Total cellular RNAs extracted from RINm5F 
cells transfected with expression plasmids carrying vector alone (lane 
1), hSSTR1 gene (clone R1-7, lane 2), and hSSTR2 gene (clone R2-14, 
lane 3), were electrophoresed on 1% agarose gel, blotted to nylon 
membranes, and hybridized with 32p-labeled hSSTR1 (left panel) and 
hSSTR2 (right panel) gene probes. The sizes of the hybridizing tran- 
scripts are indicated. (B) Binding of [125I-Tyrll]somatostatin-14 to 
RINm5F cells expressing hSSTR1 (R1-7) and hSSTR2 (R2-14). Data 
(the mean of triplicate determinations of 2 separate xperiments) have 
been normalized to account for radiolabeled ligand bound in the ab- 
sence of inhibitor (control binding, 1715 cpm for R1-7 and 1829 cpm 
for R2-14) and have been corrected for nonspecific binding (radio 
labeled ligand bound in the presence of 1 pM somatostatin, 518 cpm 
and 443 cpm in RI-7 and R2-14, respectively). Inhibition of binding 
in the presence of somatostatin (©) and SMS 201-995 (e) is shown. 
the present study were reduced by the addition of the L-type 
Ca 2+ channel blocker nifedipine (80.4 + 3.0% of control cur- 
rents at 5/tM, at a holding potential o f -80  mV, n = 7) and were 
not reduced by the addition of the N-type Ca 2÷ channel blocker 
oJ-conotoxin GVIA (96.5 + 6.1% of control currents at 10 pM,  
n = 5), the VDCC currents found in R INm5F cells are HVA 
Ca 2+ currents including L-type but not N-type. As shown in 
Figs. 2A,B and 3A, both somatostatin and SMS 201-995 signif- 
icantly inhibited the HVA Ca 2÷ currents in R2-14 cells. The 
inhibitory effects of somatostatin and SMS 201-995 were volt- 
age-dependent, as shown in Fig. 2E. The inhibition of the Ca 2÷ 
currents by these agents was most evident at test-pulse poten- 
tials between + 10 and +40 mV. In addition to the reduction in 
the peak current amplitudes, the activation process of the cur- 
rents was slowed by somatostatin and SMS 201-995 (Fig. 2A 
and B). The concentrations of somatostatin and SMS 201-995 
for inhibition of the HVA Ca 2+ currents were in reason- 
able agreement with potencies of these agents in inhibition of 
[125I-Tyr']somatostatin binding in these cells. In contrast, 
neither somatostatin or SMS 201-995 inhibited the HVA Ca 2+ 
currents in R1-7 cells (Figs. 2C and 3A) or R INm5F cells 
transfected with plasmid vector alone (control cells) (Figs. 2D 
and 3A). 
3.4. Effects of GTP),S and PTX on somatostatin- and SMS 
201-995-induced inhibition of VDCC currents in 
hSSTR2-expressing RINm5F cells 
To further investigate the mechanism by which somatostatin 
and SMS 201-995 inhibit the HVA Ca 2+ currents in R2-14 cells, 
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Fig. 2. Effects of somatostatin (SS) and SMS 201-995 (SMS) on VDCC 
currents in transfected RINm5F cells. Representative examples of 
VDCC current recordings in single RINm5F cells are shown. (A and 
B) R2-14 cells; (C) R1-7 cell; (D) RINm5F cell transfected with plas- 
mid vector alone. Control and wash indicate before and after applica- 
tion of test materials, respectively. (E) Current-voltage r lationships 
before (o), during (x), and after (e) exposure to somatostatin (SS) and 
SMS 201-995 (SMS) in R2-14 cells. Test pulse potential was +20 mV 
in A-D. 
we have used a non-hydrolysable GTP analogue, GTPyS and 
PTX to characterize the properties of the G protein that cou- 
ples SSTR2 to VDCC. When GTPyS was added to the pipette 
solution, the activation process of the HVA Ca 2+ currents de- 
tected in RINm5F cells became progressively slower and the 
peak current amplitude was reduced to 72.2 + 10.5% of control 
current (n = 5) in the first 10 min after breaking through the cell 
membrane with the patch pipette. The effect of GTPyS was 
evaluated 10-15 min after breaking through the cell membrane. 
As shown in Fig. 3B, the inhibitory effects of somatostatin a d 
SMS 201-995 on the VDCC currents in R2-14 cells were re- 
lieved by the addition of GTPyS and also by the pretreatment 
of these cells with PTX. 
3.5. Effect of  somatostatin on forskolin-induced cA MP 
production in the hSSTRl-expressing and 
hSSTR2-expressing RINm5F cells 
Since somatostatin is known to inhibit formation of cAMP 
through G i signaling in many tissues [19], we examined the 
119 
effect of somatostatin o  forskolin-induced cAMP formation 
in R1-7 and R2-14 cells. Somatostatin hibited forskolin- 
induced cAMP formation in both cells (Fig. 4) but it had no 
effect on forskolin-induced cAMP formation in control cells 
(data not shown), indicating that both hSSTRI and hSSTR2 
can be functionally coupled to adenylyl cyclase through an 
inhibitory G protein (Gi) in RINm5F cells. 
4. Discussion 
[Ca2+]i plays important roles in many cellular functions [7,8]. 
Somatostatin exerts a variety of biological effects in neurons 
and endocrine cells by inhibition of Ca :÷ influx through VDCC 
[9-12]. The diverse actions of somatostatin are mediated by its 
specific receptors. We recently have cloned five human somato- 
statin receptors (hSSTR1-5) [13-15]. In the present study we 
have found that somatostatin a d its analogue SMS 201-995 
inhibit VDCC currents detected in the rat insulinoma RINm5F 
cells stably transfected with hSSTR2 but not those transfected 
with hSSTR1. It has been reported that two types of VDCC 
currents are detected in pancreatic fl-cells and various insulin- 
secreting clonal fl-cells: a low voltage-activated (LVA) Ca 2+ 
channel and a HVA Ca 2+ channel [20]. Recent studies have 
indicated that to-conotoxin sensitive HVA Ca 2+ currents also 
are found in the RINm5F cells [21]. However, since we found 
that to-conotoxin GVIA did not inhibit VDCC currents in 
RINm5F cells used in our experiments and also that the HVA 
Ca2+currents were inhibited by somatostatin or SMS 201-995 
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Fig. 3. (A) Summary of the effects of somatostatin (SS) and SMS 
201-995 (SMS) on the VDCC currents in control (transfected with 
vector alone), RI-7, and R2-14 cells. The current amplitude obtained 
before the application of SS or SMS in each transfected cell is expressed 
as 100%. (B) Effects of GTPyS and PTX on VDCC current inhibition 
by somatostatin (SS) and SMS 201-995 (SMS) in R2-14 cells. The 
current amplitude obtained before the application of 100 nM SS or 100 
nM SMS in R2-14 cell is expressed as100%. Each value represents the 
mean + S.E.M. of 5-18 experiments forA and 3-8 experiments forB. 
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Fig. 4. Somatostatin (SS) inhibition of cAMP accumulation in 
RINm5F cells. In R1-7 cells, basal cAMP values (B) and forskolin- 
stimulated values (F) were 1.99 + 0.16 pmol/well and 9.86 + 0.99 pmol/ 
well, respectively. InR2-14 ceils, basal cAMP values (B) and forskolin- 
stimulated values (F) were 1.45 _+ 0.13 pmol/well and 9.37 _+ 0.89 pmol/ 
well, respectively. The forskolin-stimulated cAMP values were used as 
control, and values are presented as percent of control (mean + S.E.M., 
n = 3 in both cells). 
after 10 min incubation with 10/tM co-conotoxin GVIA (data 
not shown), the VDCC inhibited by somatostatin and SMS 
201-995 in RINm5F cells are HVA Ca 2+ channels other than 
N-type, probably L-type [20]. The reason why og-conotoxin 
sensitive Ca 2÷ currents were not detected in RINm5F cells in 
the present study may be due to the different subline of 
RINm5F from that examined by G. Aicardi et al. [21]. Consid- 
ering the fact that both hSSTR1 and hSSTR2 mediate the 
inhibition of cAMP accumulation and that hSSTR2 but not 
hSSTR1 mediates the inhibition of VDCC currents, it seems 
likely that a G protein other than Gi, most probably Go, serves 
as a signal transducer for the inhibition of VDCC currents 
[22,23]. In fact, we have confirmed that both Go~ 1 and Go~2 are 
present in RINm5F cells, using reverse transcriptase-polym- 
erase chain reaction (data not shown). G~r also may participate 
in the inhibition of HVA Ca :+ currents by somatostatin and 
SMS 201-995 in RINm5F cells stably expressing hSSTR2, as 
has been reported of the somatostatin action on VDCC in rat 
pituitary GH 3 cells [24,25]. 
Although SMS 201-995 has been used clinically for the treat- 
ment of endocrine tumors such as pituitary adenomas, pancre- 
atic tumors, and carcinoid, its mechanism of action is still 
unknown. We recently have determined the somatostatin re- 
ceptor subtypes expressed in various endocrine tumors and 
have found that the efficacy of SMS 201-995 in inhibition of cell 
proliferation may depend in part on the expression of hSSTR2 
[16]. Recent studies have suggested that somatostatin a d SMS 
201-995 may inhibit the cell proliferation process by activating 
phosphotyrosine phosphatase through G protein signal 
transduction [26,27]. The present study shows clearly that SMS 
201-995 as well as somatostatin have their inhibitory effect on 
VDCC currents through SSTR2 which is coupled to a PTX- 
sensitive G protein, suggesting that the inhibition of calcium 
influx through VDCC may be one of the mechanisms by which 
SMS 201-995 inhibits cell proliferation and hormone secretion 
in endocrine tumors. 
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